苑东生物
(688513)
| 流通市值：59.67亿 | | | 总市值：59.67亿 |
| 流通股本：1.77亿 | | | 总股本：1.77亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 585,013,271.79 | 682,617,697.15 | 823,669,011.35 | 781,231,030.55 |
| 应收票据及应收账款 | 250,937,841.62 | 228,637,615.55 | 174,142,121.19 | 134,271,882.33 |
| 其中：应收票据 | 17,897,555.07 | 7,142,671.46 | 12,780,834.93 | 14,093,091.71 |
| 应收账款 | 233,040,286.55 | 221,494,944.09 | 161,361,286.26 | 120,178,790.62 |
| 应收款项融资 | 70,795,231.84 | 60,642,776.78 | 41,371,272.64 | 43,432,120.25 |
| 预付款项 | 19,129,026.95 | 19,556,821.96 | 15,895,108.63 | 8,782,042.81 |
| 其他应收款合计 | 705,011.55 | 2,587,367.1 | 1,204,516.46 | 659,830.97 |
| 存货 | 184,327,814.13 | 183,466,570.14 | 174,532,106.92 | 160,981,438.25 |
| 其他流动资产 | 5,206,823.51 | 11,127,253.73 | 8,901,471.95 | 11,730,599.96 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,940,299,395.13 | 2,039,770,875.93 | 1,903,687,347.18 | 1,882,871,229.64 |
| 非流动资产: | | | | |
| 长期股权投资 | 22,743,145.31 | 23,403,475.57 | 24,537,722.44 | 24,581,213.02 |
| 其他权益工具投资 | 10,000,000 | 10,000,000 | 10,000,000 | 10,000,000 |
| 其他非流动金融资产 | 48,000,000 | 48,000,000 | 48,000,000 | 46,500,000 |
| 固定资产 | 1,012,633,401.24 | 1,029,838,838.72 | 1,050,520,529.07 | 1,068,712,955.08 |
| 在建工程 | 242,891,290.89 | 219,982,608.54 | 205,412,904.89 | 186,255,273.04 |
| 无形资产 | 33,390,884.22 | 33,809,846.18 | 34,267,706.05 | 34,458,908.98 |
| 开发支出 | 68,207,182.78 | 63,382,846.33 | 58,952,690.67 | 49,997,045.04 |
| 长期待摊费用 | 3,698,124.3 | 4,066,137.35 | 4,438,408.78 | 4,919,676.44 |
| 递延所得税资产 | 11,951,943.47 | 9,438,832.78 | 8,249,429.02 | 8,569,997.26 |
| 其他非流动资产 | 24,398,075.99 | 32,445,938.1 | 26,304,206.73 | 29,887,995.38 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,477,914,048.2 | 1,474,368,523.57 | 1,470,683,597.65 | 1,463,883,064.24 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 3,418,213,443.33 | 3,514,139,399.5 | 3,374,370,944.83 | 3,346,754,293.88 |
| 流动负债: | | | | |
| 短期借款 | 125,891,835.51 | 210,320,693.76 | 161,086,535.84 | 180,948,021.5 |
| 应付票据及应付账款 | 163,733,620.11 | 188,477,592.87 | 174,898,650.98 | 180,937,660.86 |
| 其中：应付票据 | 39,796,992.58 | 46,579,262.27 | 43,683,937 | 45,800,823.69 |
| 应付账款 | 123,936,627.53 | 141,898,330.6 | 131,214,713.98 | 135,136,837.17 |
| 合同负债 | 36,211,244.7 | 35,024,980.54 | 44,220,122.65 | 31,982,310.83 |
| 应付职工薪酬 | 38,217,113.12 | 32,340,800.65 | 26,721,440.31 | 49,968,324.5 |
| 应交税费 | 34,890,777.15 | 31,335,850.38 | 22,714,924.78 | 15,867,172.46 |
| 其他应付款合计 | 247,148,169.79 | 262,456,379.98 | 225,843,526.71 | 195,942,610.22 |
| 应付股利 | - | 29,626,400 | - | - |
| 一年内到期的非流动负债 | 2,933,333.33 | 2,933,333.33 | 2,933,333.33 | 2,933,333.33 |
| 其他流动负债 | 13,546,308.62 | 4,639,018.05 | 8,253,337.18 | 2,514,581.77 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 662,572,402.33 | 767,528,649.56 | 666,671,871.78 | 661,094,015.47 |
| 非流动负债: | | | | |
| 长期借款 | 38,160,140.74 | 38,133,333.33 | 39,635,090 | 39,600,000 |
| 递延收益 | 37,850,299.4 | 38,995,536.5 | 40,164,339.42 | 41,183,222.34 |
| 递延所得税负债 | 2,621,182.5 | 2,408,327.75 | 1,789,636.3 | 1,456,892.34 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 78,631,622.64 | 79,537,197.58 | 81,589,065.72 | 82,240,114.68 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 741,204,024.97 | 847,065,847.14 | 748,260,937.5 | 743,334,130.15 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 176,532,256 | 176,532,256 | 120,090,000 | 120,090,000 |
| 资本公积 | 1,380,694,164.03 | 1,372,160,039.12 | 1,444,304,706.77 | 1,444,304,706.77 |
| 减:库存股 | 69,450,345.25 | 4,579.37 | 54,309,920.07 | 1,592,630.81 |
| 专项储备 | 2,233,659.54 | 1,917,397.62 | 1,386,902.91 | 989,855.01 |
| 盈余公积 | 60,045,000 | 60,045,000 | 60,045,000 | 60,045,000 |
| 未分配利润 | 1,126,954,684.04 | 1,056,423,438.99 | 1,054,593,317.72 | 979,583,232.76 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,677,009,418.36 | 2,667,073,552.36 | 2,626,110,007.33 | 2,603,420,163.73 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,677,009,418.36 | 2,667,073,552.36 | 2,626,110,007.33 | 2,603,420,163.73 |
| 负债和股东权益合计 | 3,418,213,443.33 | 3,514,139,399.5 | 3,374,370,944.83 | 3,346,754,293.88 |
| 公告日期 | 2024-10-25 | 2024-08-20 | 2024-04-23 | 2024-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |